Clinical Trials · NCT03712098
Daily Liraglutide for Nicotine Dependence
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Rebecca Ashare
- Enrollment
- 40
- Start date
- Nov 2018
- Locations
- 1 site, United States
- Primary endpoint
- Number of Participants With 7-day Point Prevalence Smoking Abstinence at 12 Weeks Post-Target Quit Date